Log in

Relevant bibliographies by topics / Kaposi's disease

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'Kaposi's disease'

Author: Grafiati

Published: 25 May 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Kaposi's disease.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Kaposi's disease"

1

Santos, Mônica, Virginia Vilasboas, Luciana Mendes, Carolina Talhari, and Sinésio Talhari. "Lymphangiectatic Kaposi's sarcoma in a patient with AIDS." Anais Brasileiros de Dermatologia 88, no. 2 (April 2013): 276–78. http://dx.doi.org/10.1590/s0365-05962013000200019.

Full text

Abstract:

Kaposi's sarcoma is a malignant disease that originates in the lymphatic endothelium. It has a broad spectrum of clinical manifestations. Its four distinct clinical forms are: classic, endemic, iatrogenic and epidemic Kaposi's sarcoma. In non-HIV-associated Kaposi's sarcoma, the disease is typically limited to the lower extremities, but in immunodeficient patients, it is a multifocal systemic disease. The clinical course of the disease differs among patients, ranging from a single or a few indolent lesions to an aggressive diffuse disease. Advanced Kaposi's sarcoma lesions, typically those on the lower extremities, are often associated with lymphedema. In this paper, we report a case of a patient with a rare form of AIDS-associated Kaposi sarcoma called lymphangiectatic Kaposis's sarcoma.

APA, Harvard, Vancouver, ISO, and other styles

2

Murthy MS, Cody Lawrence, Todd Brown, and Shanika Sharma. "Presence of Kaposi's Sarcoma and of Behcet’s Disease Concomitantly in a Patient." International Healthcare Research Journal 6, no. 12 (March 12, 2023): RV1—RV3. http://dx.doi.org/10.26440/ihrj/0611.02591.

Full text

Abstract:

Iatrogenic Kaposi’s sarcoma is a subtype of Kaposi’s sarcoma (KS), which is a vascular malignant tumor and is seen in organ transplant recipients and in patients receiving immunosuppressive therapy due to other reasons. We describe a case of Behcet's disease associated with Kaposi's sarcoma occurring simultaneously in a 50-year-old male patient. Colchicine and steroids were administered for his mucocutaneous findings and polyarthritis. In few months on therapy, four symmetric, brown- red coloured, asymptomatic macules developed on the inner surface of his left foot. In histopathologic specimens; CD34 positive, atypical spindle cells with swollen nuclei formed bundles and vascular spaces filled with erythrocytes. The patient was diagnosed as KS clinically and histopathologically. HHV-8 DNA was positive with PCR. Regression was observed in the lesions after the cessation of corticosteroid treatment.

APA, Harvard, Vancouver, ISO, and other styles

3

Grabovskaya, Olga V., Natalia P. Teplyuk, Sergey A. Mishin, Ekaterina V. Grekova, Ekaterina R. Dunaeva, Alina V. Perekhodova, and Lidia M. Shnakhova. "Kaposi's sarcoma: Problems of differential diagnosis." Russian Journal of Skin and Venereal Diseases 26, no. 5 (November 17, 2023): 487–95. http://dx.doi.org/10.17816/dv492311.

Full text

Abstract:

Kaposi's sarcoma is a multifocal malignant disease of vascular origin with a primary lesion of the skin, as well as internal organs and lymph nodes. According to various authors, it is believed that Kaposi's sarcoma is associated with herpes simplex virus type 8 (HHV-8). According to the literature, the following types of Kaposi's sarcoma are distinguished: classical (European), immunosuppressive, endemic (African) and epidemic (this form of sarcoma is associated with the state of acquired immunodeficiency). Clinically, with Kaposi's sarcoma, rashes can vary depending on the form of the disease, among which there are spotty, papular and tumor forms. Also in the literature, some authors distinguish the 4th form of Kaposi's sarcoma ― bullous. Diagnostic search for Kaposi's sarcoma is a difficult problem due to the large number of diseases of vascular origin, as well as their clinical similarity. The diagnostic methods described in the literature include many studies, including a blood test for HHV-8, as well as routine histological examination and immunohistochemistry. The article presents a rare clinical case of Kaposi's sarcoma in a young girl with a long history of the disease.

APA, Harvard, Vancouver, ISO, and other styles

4

Corda, L., D. Benerecetti, M. Ungari, F. Facchetti, and E. Radaeli. "Kaposi's disease and sarcoidosis." European Respiratory Journal 9, no. 2 (February 1, 1996): 383–85. http://dx.doi.org/10.1183/09031936.96.09020383.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

OLIVEIRA, H., C. MONTEIRO, and A. FIGUEIREDO. "FC135 Iatrogenic Kaposi's disease." Journal of the European Academy of Dermatology and Venereology 9 (September 1997): S147. http://dx.doi.org/10.1016/s0926-9959(97)89456-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Koyuncu, Ismail, Ataman Gönel, Emrah Ozcan, Ebru Temiz, Şahin Toprak, Feridun Akkafa, and Irfan Binici. "Single Nucleotide Polymorphism Analysis in HIV and Kaposi's Sarcoma Disease by Microarray Technique." Current HIV Research 18, no. 3 (June 12, 2020): 154–64. http://dx.doi.org/10.2174/1570162x18666200130100654.

Full text

Abstract:

Background: Emergence of Kaposi's Sarcoma in the cases other than HIV, following the use of immunosuppressant drugs, demonstrates that it is related to weak immunity. The fact that this malignancy does not occur in every HIV-positive patient suggests that genetic predisposition may also be effective. Replacement of one of the base pairs of adenine, guanine, cytosine, and thymine that constitute the DNA sequence in the human genome with another base pair can affect susceptibility to disease, response to treatment, and immunity. Objective: The purpose of this study is to analyze the Single Nucleotide Polymorphism that could predispose to Kaposi's sarcoma of an HIV-infected patient and to identify which nucleotides such SNPs correspond to, using the microarray technology. Material and Method: The blood samples of individuals, one of whom was diagnosed with Kaposi's Sarcoma HIV (+) visiting the outpatient clinic of infectious diseases polyclinic of Harran University Research and Practice Hospital and of a healthy individual with no Kaposi's Sarcoma, were used in the study. Following the DNA isolation of the blood samples taken from the respective individuals, a SNP analysis was conducted on the microarray device. 204,000 SNPs obtained were scanned later on in the databases in an attempt to identify the SNPs related to Kaposi's Sarcoma. Results: In the 204,000 SNP screenings, we scrutinized the SNPs that differ in the case of Kaposi's Sarcoma [KS (+) and HIV (+)] on the basis of Control [KS(-) and HIV(-)] and HIV+ [KS(-)], and two SNPs of the ENDRA gene, three SNPs of the ADRA1A gene, six SNPs of the STIM1 gene, four SNPs of the EFNB2 gene, and one SNP of the CD209 gene were found to be different. However, when it comes to all SNPs (all the 204.000 SNPs) screened in terms of allele, it was observed that the AA and BB alleles were lower in the patient with Kaposi's Sarcoma [KS (+) and HIV (+)] compared to other groups and AB alleles were found to be higher than others in the patient with Kaposi's sarcoma [KS] (+) and HIV (+)]. Conclusion: In the microarray study we have conducted, 204,000 SNPs were screened for Control (HIV-) HIV (+) and HIV (+) patient with Kaposi's Sarcoma. It was found that 32,362 of those SNPs had different alleles in the Kaposi's Sarcoma [KS + HIV (+)] patient, while they had the same ones in the control [KS (-) and HIV (-)] and HIV + [KS (-)] group. 16 of the 32,362 SNPs took place among the genes related to Kaposi's Sarcoma. In the cases of Kaposi's Sarcoma with suspected diagnosis, it can be used as a beneficial laboratory test.

APA, Harvard, Vancouver, ISO, and other styles

7

Grishina, E. E. "Kaposi’s sarcoma with the eyelid involvement (6 clinical cases)." Almanac of Clinical Medicine 46, no. 4 (September 26, 2018): 390–94. http://dx.doi.org/10.18786/2072-0505-2018-46-4-390-394.

Full text

Abstract:

Kaposi's sarcoma is a multifocal tumor from vascular endothelium with a low grade of malignancy. It develops due to underlying immune deficiency and is associated with human herpesvirus 8. Kaposi's sarcoma of the eyelids is rare, and its diagnosis can be difficult both for ophthalmologists and oncodermatologists. The paper describes six clinical cases of Kaposi's sarcoma with involvement of the eyelids. Three patients had an HIV-associated type of the tumor. One patient had an immunosuppressive type of the tumor during immunosuppressive treatment after kidney transplantation. Two elderly patients had Kaposi's sarcoma of the classic type. Tumors of the eyelids developed after several years of skin involvement. All patients had advanced (nodular) stage of Kaposi's sarcoma of the eyelids, whereas the skin tumors looked as spots (maculas) or papules (macular or papular stage of the disease). The eyelid tumor presented as an extensive dark red tumor nodule distinctly separate from the adjacent tissues. In all cases, the eyelid tumor was big and hindered the sight. All the patients were treated by an oncodermatologist and/or a specialist in infectious diseases, depending on the clinical type of the disease. Kaposi's sarcoma rarely involves the eyelid skin or conjunctiva; however, in immunodeficient patients it must be included into the list for the differential diagnosis of eyelid tumors.

APA, Harvard, Vancouver, ISO, and other styles

8

Sterling, Glenn B. "Kaposi's sarcoma and Castleman's disease." Journal of the American Academy of Dermatology 22, no. 1 (January 1990): 144. http://dx.doi.org/10.1016/s0190-9622(08)80030-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Koldarova, Evelina, Bahrambek Mukhamedov, and Aziz Aliev. "A clinical case of an immunosuppressive generalized form of Kaposi's sarcoma in a patient with pemphigus vulgaris." Journal of Clinical Medicine of Kazakhstan 19, no. 6 (December 30, 2022): 100–103. http://dx.doi.org/10.23950/jcmk/12695.

Full text

Abstract:

The article presents the literature data on Kaposi's sarcoma a lymphangioproliferative neoplasia induced by the Herpes Virus type 8.  The main forms, clinical manifestations and treatment are described. A clinical case of the development of an immunosuppressive generalized form of Kaposi's sarcoma induced by glucocorticosteroid therapy in a patient with pemphigus vulgaris is presented. With this clinical example, it is important to emphasize the potential risk of Kaposi's sarcoma on the background of secondary immunosuppression. Immunosuppressive Kaposi's sarcoma (iatrogenic type) is most often associated with long-term use of immunosuppressive therapy in transplantation organs and in patients receiving immunosuppressive therapy for autoimmune diseases, which leads to an increased risk of developing Kaposi's sarcoma by 150-1000 times compared with the general population. The ratio of men and women with this type is 2:1, while with the idiopathic (classical) - 17:1. Reliable diagnosis of the disease is necessary, based on a combination of history data, clinical and histological patterns of the pathological process, as well as additional laboratory markers, which will allow timely determination of further patient management tactics and, accordingly, provide a more favorable prognosis for the course of the disease.

APA, Harvard, Vancouver, ISO, and other styles

10

Steinfeld, AD, and JS Cooper. "Epidemic and classic Kaposi's sarcoma of the feet. A comparative study." Journal of the American Podiatric Medical Association 80, no. 9 (September 1, 1990): 469–70. http://dx.doi.org/10.7547/87507315-80-9-469.

Full text

Abstract:

The clinical behavior of Kaposi's sarcoma involving the feet is compared for patients with and without AIDS. Although AIDS-related Kaposi's sarcoma is less likely to be confined to the legs than is non-AIDS-related Kaposi's sarcoma, the legs are the most common site of disease in both forms. Kaposi's sarcoma occurring in the AIDS setting is as radiosensitive as that which occurs in the patient without AIDS. Palliative radiotherapy can offer substantial relief for affected patients.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Kaposi's disease"

1

Wiggins, Charles Lamar. "Kaposi's sarcoma and sexually transmitted disease /." Thesis, Connect to this title online; UW restricted, 1999. http://hdl.handle.net/1773/10933.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Kimball, Louise Elizabeth. "Humoral immune response to Kaposi's sarcoma-associated herpesvirus in persons with and without Kaposi's sarcoma /." Thesis, Connect to this title online; UW restricted, 2003. http://hdl.handle.net/1773/9284.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Hong, Angela M. "Cell cycle protein expression in AIDS-related and classical Kaposi's sarcoma." Connect to full text, 2004. http://hdl.handle.net/2123/583.

Full text

Abstract:

Thesis (Ph. D.)--University of Sydney, 2004.
Title from title screen (viewed 5 May 2008). Submitted in fulfilment of the requirements for the degree of Doctor of Philosophy to the Faculty of Medicine. Includes list of published articles and presentations. Includes bibliographical references. Also available in print form.

APA, Harvard, Vancouver, ISO, and other styles

4

Kakoola, Dorothy Nalwanga. "Human herpesvirus 8 in Uganda : seroprevalence in blood donors, genome variability and evolution." Thesis, University of Glasgow, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.366192.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Speicher, David Jeremiah. "Detection and Genotyping of HHV-8 in Australia and Kenya: Disease Associations with Special reference to Kaposi's Sarcoma and Castleman's Disease." Thesis, Griffith University, 2012. http://hdl.handle.net/10072/367862.

Full text

Abstract:

HHV-8, the aetiological agent of Kaposi’s sarcoma (KS), multicentric Castleman’s disease (MCD) and primary effusion lymphoma (PEL) has been characterised in several parts of the world but largely overlooked in Australia, perhaps because highly active antiretroviral therapy (HAART) has drastically reduced the incidence of HHV-8-associated diseases in the most at-risk population, namely those with HIV disease. Previously, Australian researchers have looked briefly at the sexual behaviours associated with risk of transmission of HHV-8, at molecular methods for detecting the presence of this virus, and have genotyped just eight clinical isolates. Now, the re-emergence of HHV-8 disease associated with increased lifespan in HIV-positive individuals has created a need to better understand the biological importance of this virus, including in Australia and in the developing world. While report of KS and HHV-8 have been previously published from Australia, this project establishes the first research group devoted to the understanding of HHV-8 from an Australian perspective, develops validated quantitative molecular detection methods for HHV-8 in blood and oral fluids, and then characterises the viruses detected via phylogenetic analyses.
Thesis (PhD Doctorate)
Doctor of Philosophy (PhD)
School of Dentistry and Oral Health
Griffith Health
Full Text

APA, Harvard, Vancouver, ISO, and other styles

6

Blumenthal, Melissa. "Characterisation of Kaposi's sarcoma-associated herpesvirus (KSHV)-driven pathology and disease outcome in HIV infected South African patients." Doctoral thesis, Faculty of Health Sciences, 2020. http://hdl.handle.net/11427/32202.

Full text

Abstract:

Kaposi's sarcoma-associated herpesvirus (KSHV), a gamma-herpesvirus with a particularly high seroprevalence in Sub-Saharan Africa (SSA), is the etiological agent of the endothelial tumour Kaposi's sarcoma (KS), the most common acquired immunodeficiency syndrome (AIDS)-related malignancy worldwide and particularly in SSA. It also causes primary effusion lymphoma (PEL), multicentric Castleman disease (MCD) and KSHV inflammatory cytokine syndrome (KICS). AIDS-related deaths have declined, due to global scale-up of antiretroviral therapy (ART). However, the vast majority of these occurred in SSA, where tuberculosis (TB) is the leading cause of mortality among human immunodeficiency virus (HIV)-infected individuals, accounting for a third of all AIDS-related deaths. The exceptionally high burden of suspected TB in SSA causes misdiagnosis or delayed diagnosis of diseases mimicking TB, such as several pathologies associated with KSHV. KSHV infection is essential but insufficient for the development of KS and other KSHV-associated pathologies; precipitating factors, such as HIV-related immune suppression and potentially genetic predisposition, are required. The erythropoietin-producing hepatocellular carcinoma (Eph) receptor A2 protein (EPHA2) tyrosine kinase receptor is a promising candidate for studies on genetic variants as it potentially acts on two levels: susceptibility to KSHV infection (being one of the key receptors utilised by KSHV for cell entry and intracellular trafficking) and susceptibility to KS development (being implicated in oncogenesis). Despite the high seroprevalence in SSA, the contribution of dysregulated KSHV lytic replication or host KSHV receptor variations to disease outcome in HIV-infected patients is unknown. We hypothesised that KSHV lytic reactivation plays yet unrecognised roles for morbidity and mortality in high HIV settings and to this end, we conducted a cohort study of 682 HIV-positive critically ill patients admitted to Khayelitsha Day Hospital, South Africa, investigated for TB, and followed for 12-weeks to ascertain vital status. We demonstrated that elevated blood KSHV viral load (VL) was a strong predictor of death in hospitalised HIV-infected patients without microbiologically proven TB. Further, we identified and validated variants in the EPHA2 protein tyrosine kinase and sterile alpha motif domains that were significantly associated with susceptibility to infection, KS development and/or KSHV VL in 300 South African HIV-infected patients, by aggregate by-gene analysis. In order to elucidate the functional significance of the identified EPHA2 missense mutations, we knocked out endogenous EPHA2 by CRISPR/Cas9 in the human endothelial cell line, HuARLT2, and reintroduced the wild type and mutant EPHA2 open reading frames by lentiviral transduction. These engineered cells were assessed for baseline EPHA2 phosphorylation levels and susceptibility to KSHV infection utilising recombinant KSHV in binding, internalisation and infection assays. We found that the EPHA2 mutant c.2254T>C (p.Leu700Pro) in the tyrosine kinase domain, associated with KS in our patient cohort, was deficient in tyrosine phosphorylation and less permissive to rKSHV infection when introduced as a single mutation or as a double mutant together with c.2257A>C (p.Asp701Ala) which was found to be in linkage disequilibrium with it. Another tyrosine kinase domain variant, c.2688G>S (p.Ala845Pro), found to be overrepresented among KS patients, had enhanced baseline tyrosine phosphorylation levels. These findings validated the patient-derived data on the molecular level by assigning functional consequences to some mutants which might have implications for the development of future biomarkers predicting KS susceptibility in high-risk populations. In summary, this novel research contributes to the understanding of KSHV-associated pathology and disease outcome. It identified KSHV VL as a potential biomarker to predict KSHV-associated diseases and mortality and assessed the contribution of KSHV entry receptor EPHA2 variations to KSHV-associated pathologies, with potential clinical implications, by facilitating the development of novel diagnostic and surveillance tools.

APA, Harvard, Vancouver, ISO, and other styles

7

Magri, Mariana Cavalheiro. "Prevalência de anticorpos anti-herpesvírus humano tipo 8 (HHV-8) em soros de pacientes com insuficiência renal crônica." Universidade de São Paulo, 2008. http://www.teses.usp.br/teses/disponiveis/9/9136/tde-25072008-144452/.

Full text

Abstract:

A infecção pelo herpesvírus humano tipo 8 (HHV-8) tem sido associada ao sarcoma de Kaposi (SK) iatrogênico, que acomete pacientes imunossuprimidos e/ou transplantados renais. Em populações consideradas saudáveis, a soroprevalência para o HHV-8 varia de 1% a 8%. O presente trabalho buscou: determinar a prevalência e os títulos de anticorpos anti-HHV-8 em pacientes com insuficiência renal crônica (IRC), submetidos ou não à terapia renal substitutiva (TRS) do Hospital do Rim e Hipertensão e Casa da Diálise da UNIFESP e da Santa Casa de Misericórdia de São Paulo e, comparar os resultados obtidos com outras populações da mesma região geográfica, porém de outras categorias de risco para adquirir doenças infecciosas. Soros de 805 pacientes: 295 em hemodiálise, 54 em diálise peritoneal e 456 em acompanhamento ambulatorial, sem TRS, foram testados quanto à presença de anticorpos anti-HHV-8, de fase latente e lítica da replicação viral, por meio de técnicas de imunofluorescência indireta (IFI) LANA e Lítico, padronizadas na Seção de Imunologia do Instituto Adolfo Lutz. Os resultados obtidos foram analisados em relação a dados clínicos, epidemiológicos e laboratoriais usando o teste do qui-quadrado ou exato de Fisher para as variáveis categóricas e os testes de Mann Whitney ou Kruskal Wallis para as variáveis contínuas. Foi encontrada soropositividade ao HHV-8 em 18,0% dos pacientes com IRC, dos quais 18,3% nos pacientes em TRS e 17,7% nos pacientes sem TRS, não havendo diferença significante entre os grupos. As variáveis que estiveram relacionadas à sorologia positiva ao HHV-8 foram: transplante prévio (p<0,001) e doenças sexualmente transmissíveis (p=0,003), com destaque para a sífilis (p=0,021). As demais variáveis não mostraram associação estatística embora tenha havido maior número de amostras HHV-8 soropositivas com o avançar da idade. Em relação ao tipo e ao título de anticorpos detectados, houve mais amostras com sorologia positiva para anticorpos Lítico e maiores títulos de anticorpos LANA. A comparação dos resultados dos pacientes com IRC e outras populações de São Paulo revelou taxa semelhante de prevalência de anticorpos anti-HHV-8 na população com HIV/Aids (20,4%), considerada de alto risco para esta infecção viral. Por outro lado, a prevalência detectada na população com IRC (18,0%) foi inferior às obtidas em pacientes com SK epidêmico (89,3%), SK clássico (100,0%) e SK endêmico (87,5%), e superior a outras populações sem SK: pacientes com deficiência mental e/ou física (1,6%) e profissionais da área da saúde (1,1%). Em todos os grupos analisados houve maior número de amostras com sorologia positiva para HHV-8 de fase lítica, e maiores títulos de anticorpos LANA, exceção feita aos profissionais da área da saúde. Maiores títulos de anticorpos LANA foram detectados nos pacientes com SK. Não foram encontradas outras associações significantes. Os resultados obtidos permitem concluir que os pacientes com IRC têm alta prevalência de anticorpos anti-HHV-8, comparável aos indivíduos com HIV/Aids dessa região geográfica. Ainda, sugerem que se devam acompanhar os pacientes HHV-8 soropositivos com vistas a monitorar os títulos de anticorpos LANA e verificar se estes têm valor prognóstico. Caso isto venha a ser confirmado, sugere-se a introdução da sorologia para o HHV-8 na bateria de exames do pré-transplante renal.
Human herpesvirus 8 (HHV-8) infection is frequently associated with Kaposi\'s sarcoma (KS) in immunodeficient and renal transplanted patients. The HHV-8 seroprevalence in healthy populations varies from 1% to 8%. The present study aimed to determine the HHV-8 seroprevalence and antibodies titers in chronic kidney disease (CKD) patients with or without substitutive kidney therapy (SKT) attended at Hospital do Rim e Hipertensão and Casa da Diálise of UNIFESP, and at Santa Casa de Misericórdia de São Paulo. Secondarly, to compare the serological results with those obtained from populations of the same geographic region, presenting other risk factors for acquiring infectious diseases. Serum samples were collected from 805 CKD patients: 295 under hemodialysis, 54 under peritoneal dialysis, and 456 in ambulatorial assistance without SKT. Latent and Lytic HHV-8 antibodies were searched using indirect immunofluorescence assays that were standardized at Immunology Department of Instituto Adolfo Lutz. Chi-Square test and/or Fisher\'s exact test were performed for comparing categorical variables including epidemiological, clinical and laboratorial data, and HHV-8 serum status. Continuos variables associated with HHV-8 antibodies titers were compared using Mann Whitney or Kruskal Wallis tests. An overall HHV-8-seropositivity of 18.0% was detected in CKD patients: 18.3% in patients under SKT and 17.7% in patients without SKT. Since no difference was detected in HHV-8-seropositivity among patients, they were considered as a unique group for subsequent analysis. A strong association between HHV-8-seropositivity and previous transplant was detected (p<0.001), along with an association with others sexually transmitted diseases (p=0.003), with emphasis for syphilis (p=0.021). In addition, no other data was associated with HHV-8-seropositivity, although higher proportions of HHV-8-seropositivity were detected in samples from elderly persons. In addition, more HHV-8 Lytic antibodies positive samples, and higher titers of LANA antibodies were detected. HHV-8 seroprevalence obtained from CKD patients was similar to the HHV-8 prevalence detected among HIV/Aids patients (20.4%), who were considered a high-risk group for this viral infection. On the other hand, the HHV-8 seroprevalence of CKD patients (18.0%) was lower than the prevalence of patients with epidemic KS (89.3%), classic KS (100.0%) and endemic KS (87.5%), and higher than the patients with mental and/or physical deficiency (1.6%) and health professionals (1.1%). All analyzed groups had more HHV-8-seropositive samples for Lytic antibodies and higher titers of LANA antibodies, with exception for the health professionals. The highest LANA antibodies titers were found among KS patients groups. No other association was found. In conclusion, the obtained results points out CKD patients as a high prevalent population for HHV-8 infection, similar to HIV/Aids patients from the same geographic area. As far, it suggests that HHV-8 seropositive CKD patients should be followed up in order to verify whether LANA antibodies titers have prognostic value. In confirming this hypothesis, it may propose to include the use of HHV-8 serology in the screening testing in kidney pre-transplant.

APA, Harvard, Vancouver, ISO, and other styles

8

Kohlhorst, Drew Eric. "Bartonella Bacilliformis: Understanding The Underlying Causes Of Verruga Peruana Formation During Carrion’s Disease." Digital Archive @ GSU, 2008. http://digitalarchive.gsu.edu/biology_diss/37.

Full text

Abstract:

Bartonella, a group of Gram negative facultative intracellular bacteria, are known to cause diseases, such as Cat Scratch Disease, Trench Fever and Carrion’s Disease, that involve angiogenesis during the infective cycle. B. bacilliformis, the etiological agent of Carrion’s Disease, causes a bi-phasic infection resulting in the formation of blood-filled angiogenic proliferative cutaneous nodules called verruga peruana. The work presented here was undertaken to characterize the mechanism by which these nodules are produced. Previous work in our laboratory suggested that the Bartonella henselae genome contains a homologue to the virB operon, a set of genes coding for a Type IV Secretion System (TFSS) that has been implicated in the pathogenesis of other α-2-proteobacteria. We identified virB operons in two additional Bartonella pathogens, B. quintana and B. clarridgeiae. No corresponding operon sequences were detected in B. bacilliformis DNA, however. This finding suggests that virB gene products are not required for verruga peruana formation. To continue our search for factors involved in B. bacilliformis-induced angiogenesis, we conducted a microarray analysis of differential gene expression in infected and uninfected endothelial cells. The results suggest similarities between later stage (36 hours) B. bacilliformis infection and that of HHV-8, the causative agent of Kaposi’s Sarcoma, particularly in relation to the host immune response. Finally, our research focused on the secreted factors that B. bacilliformis produces during its host infective cycle. Our data suggest that the B. bacilliformis homologue to the molecular chaperone GroEL not only induces angiogenesis in endothelial cells, but also protects endothelial cell tubule from the degradation seen when these cells are in the presence of live B. bacilliformis. In summary, the induction of verruga peruana nodules via B. bacilliformis may be the result of multiple factors over the course of persistent infection. Early infection may cause vascular damage, which induces VEGF and hypoxia factors. As infection persists, bacterial secretion of a unique GroEL may result in continued angiogenesis and the ensuing activation of immune cells, producing a localized environment of continual incomplete angiogenesis in areas of cutaneous infection.

APA, Harvard, Vancouver, ISO, and other styles

9

Viollet, Coralie. "Dissecting the interactive effects of hypoxia and Kaposi's sarcoma-associated herpesvirus on microRNA and mRNA transcriptomes." Thesis, University of Oxford, 2015. http://ora.ox.ac.uk/objects/uuid:602498b1-f1fb-4677-be91-14dd5add728b.

Full text

Abstract:

Kaposi's sarcoma-associated herpesvirus (KSHV) causes several tumours and hyperproliferative disorders. Hypoxia plays an important role in KSHV lifecycle, as hypoxia-inducible factors (HIFs) are involved in the latent/lytic switch and affect other KSHV genes, and as KSHV infection can in turn enhance cellular levels of HIFs. Two KSHV-associated tumours tend to develop in settings of relative hypoxia; Kaposi's sarcoma (KS) often occurs in the lower extremities and primary effusion lymphoma (PEL) exists in pleural effusions. A better knowledge of the pathways that regulate KSHV infection in hypoxia is therefore essential for an improved understanding of viral infection and pathogenesis. MicroRNAs (miRNAs) have been shown to play important roles in regulating the expression of genes in oncogenesis, and herpesviruses, including KSHV, encode for miRNAs. This thesis describes a multidisciplinary approach toward understanding the mechanisms behind the hypoxia-regulated miRNA-mRNA networks in the context of KSHV infection. The question of miRNA and mRNA regulation through hypoxia, KSHV or both is addressed in this thesis by deep sequencing and gene expression assays as well as various transfection and functional assays. In chronically infected cells compared to uninfected controls, it is demonstrated that the majority of cellular miRNAs whose expression is affected are substantially down-regulated. A third of this down-regulation can be attributed to a single genomic region, 14q32 cluster, where miRNAs are lowly expressed in infected cells. In hypoxia, hsa-miR-210 is the only miRNA to be consistently up-regulated in the KSHVinfected cell lines subjected to deep sequencing in this study. Computational approaches additionally allowed for the investigation of mRNA targets. Inversely correlated miRNAmRNA target pairs were identified and distributed into canonical pathways and biological networks. Taken together, these results suggest that miRNAs affected by hypoxic stress and/or viral infection are implicated in the pathogenesis of KSHV-related diseases. It is expected that the outcomes of these studies will change our understanding of how KSHV uses the host RNA silencing machinery to its advantage and how this intersects with the use of the cell's response to hypoxia.

APA, Harvard, Vancouver, ISO, and other styles

10

Bailer, Robert T. "Human T-lymphotrophic virus types I/II in autoimmune diseases, growth characteristics and cytokine expression in AIDS-related Kaposi's sarcoma derived cell strains and patients, and constitutive cytokine expression in HTLV and STLV.. /." The Ohio State University, 1994. http://rave.ohiolink.edu/etdc/view?acc_num=osu1487856076415404.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Kaposi's disease"

1

J, Gottlieb Geoffrey, and Ackerman A. Bernard 1936-, eds. Kaposi's sarcoma: A text and atlas. Philadelphia: Lea & Febiger, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

G, Giraldo, ed. Recent advances in AIDS and Kaposi's sarcoma. Basel: Karger, 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Lehnherr, Melinda. Kaposi's sarcoma in Illinois: A comparison of AIDS cases to classic cases. Springfield, Ill: Illinois Dept. of Public Health, Division of Epidemiologic Studies, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

G, Castello, ed. Sindrome di immunodeficienza acquisita e sarcoma di Kaposi (AIDS/KS). Firenze: USES, Edizioni scientifiche, 1986.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Shepherd, Frances A. Management of Kaposi's sarcoma associated with human immunodeficiency virus infection: Report. [Ottawa]: Health and Welfare Canada, 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Canada. Health and Welfare Canada. Management of Kaposi's Sarcoma associated with human immunodeficiency virus infection/ Francis A. Shepard. Ottawa: Health and Welfare Canada, 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

G, Giraldo, World Health Organization, and International Symposium on AIDS and Associated Cancers in Africa (2nd : 1987 : Naples, Italy), eds. AIDS and associated cancers in Africa: 2nd international symposium, Naples, October 7-9, 1987. Basel: Karger, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

1925-, Vaeth Jerome M., ed. Cancer and AIDS: 19th annual San Francisco Cancer Symposium, San Francisco Calif., March 2-4, 1984. Basel: Karger, 1985.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

AIDS, the acquired immune deficiency syndrome. 2nd ed. Lancaster [Lancashire]: MTP Press, 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Daniels, Victor G. SIDA, sindrome de immunodeficiencia adquirida. 2nd ed. México: Manual Moderno, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Kaposi's disease"

1

Vaccaro, Mario, Claudio Guarneri, Richard F. Ambinder, S. Diane Hayward, Marcia Spinelli Casanova, Oladapo Adewuya, Ferid Murad, et al. "Kaposi’s Sarcoma." In Encyclopedia of Molecular Mechanisms of Disease, 1110–12. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-540-29676-8_992.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Tschachler, Erwin. "Kaposi’s Sarcoma." In Sexually Transmitted Infections and Sexually Transmitted Diseases, 405–9. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-14663-3_31.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Crowe, David R. "Kaposi Sarcoma." In Deadly Dermatologic Diseases, 61–66. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-31566-9_9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Chung, Christina Lee, and Carla Ferrándiz-Pulido. "Kaposi Sarcoma." In Atlas of Dermatologic Diseases in Solid Organ Transplant Recipients, 367–87. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-13335-0_15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Moore, Patrick S., and Yuan Chang. "Introduction to Diseases Associated with Kaposi’s Sarcoma-Associated Herpesvirus." In DNA Tumor Viruses, 441–68. New York, NY: Springer US, 2008. http://dx.doi.org/10.1007/978-0-387-68945-6_18.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Itakura, Hideyo, and Kan Toriyama. "Geopathological Coincidence of Burkitt’s Lymphoma and Endemic Kaposi’s Sarcoma in Western Kenya." In Epstein-Barr Virus and Human Disease, 453–54. Totowa, NJ: Humana Press, 1987. http://dx.doi.org/10.1007/978-1-4612-4590-2_97.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Poudyal, Rosha, Rolf Renne, and Michael P. Kladde. "Epigenetic Regulation of Gammaherpesviruses: A Focus on Kaposi’s Sarcoma-Associated Herpesvirus (KSHV/HHV-8)." In Epigenetics of Infectious Diseases, 15–46. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-55021-3_2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Goh, Yet Ching. "Reddish Growths on the Hard Palate: Kaposi Sarcoma." In Clinicopathological Correlation of Oral Diseases, 141–49. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-24408-7_13.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Dittmer, Dirk P., and Blossom Damania. "Kaposi’s Sarcoma-Associated Herpesvirus (KSHV)-Associated Disease in the AIDS Patient: An Update." In Cancer Treatment and Research, 63–80. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-030-03502-0_3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Cesarman, Ethel. "The Role of Kaposi’s Sarcoma-Associated Herpesvirus (KSHV/HHV-8) in Lymphoproliferative Diseases." In Immunosurveillance, Immunodeficiencies and Lymphoproliferations, 27–37. Berlin, Heidelberg: Springer Berlin Heidelberg, 2002. http://dx.doi.org/10.1007/978-3-642-56352-2_4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Kaposi's disease"

1

Lefrere, J. J., D. Vittecoq, D. Gozin, and J. Modai. "CIRCULATING ANTICOAGULANT IN AIDS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644859.

Full text

Abstract:

The frequency of a circulating anticoagulant has been reported to be high in AIDS, in particular in case of Pneumocystic carinii pneumonia (Pep). Twenty-five non-hemophiliac patients (23 homosexual males,1 drug addict, 1 tranfused) with AIDS were followed over a six month period. Mean age was 32 (21-42). All patients had a markedly decreased T4/T8 ratio (mean 0.12), a low absolute T4 level (mean : 155/mm3), an elevated total serum immunoglobulins level.Activated partial thromboplastin time (APTT), prothrombintime and thrombin time were measured once a week during hospitalisation. A prolonged APTT (more than 10 seconds as compared to controls) with normal prothrombin time and thrombin time was found only once in 11patients and in two or more occasions in two others.No specific factor level of intrinsic pathway wasfound low enough to explain a prolonged APTT.Evidenceofcirculating anticoagulant (failure to correct aprolonged APTT by equal mixure of normal plasma and patient plasma) was found in all these 13 patients.Nothrombotic or haemorraghic manifestations occured.AIDS manifestations were 2 Pep.1 cytomegalovirus retinitis. 2 Kaposi's sarcomas, 1 Hodgkin's disease, 2 mycobacterium avium intracellulare pulmonary infection, 4 central nervous system toxoplasmosis, 1 Cryptococcus meningitis. Amongst the 12 patients with normal APTT,3_Pcp, 2 cytomegalovirus retinitis. 2 Kaposi's sarcomas, 2 central nervous system toxoplasmosis, 1 unexplained fever, and 2 oesophagus candidiasis were diagnosed. A transiently prolonged APTT associated to a circulating inhibitor seems to be common in AIDS. Weobserved this anomaly in 52 % (13/25). In our five cases of Pcp, 3 had normal APTT. During other opportunistic infections, the circulating inhibitor was found.The similar complications seen in two groups suggest that a circulating anticoagulant is not specifically associated to any opportunistic infection and any malignancybut appearr independently from these circumstances.

APA, Harvard, Vancouver, ISO, and other styles

2

Everstine, A., and M. E. Richert. "Overcoming the Cytokine Storm: Unusual Case of Kaposi Sarcoma Herpes-Associated Multicentric Castleman Disease." In American Thoracic Society 2024 International Conference, May 17-22, 2024 - San Diego, CA. American Thoracic Society, 2024. http://dx.doi.org/10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a7492.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Qin, Zhiqiang, Lu Dai, Momka Bratoeva, Bryan Toole, and Chris Parsons. "Abstract LB-435: Regulation of emmprin in Kaposi's sarcoma-associated herpesvirus (KSHV)-infected cells: a novel strategy developed against KSHV-related diseases." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-lb-435.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!